Medicina genómica aplicada a la neumonía aguda comunitaria

  • Pablo Cardinal CASMU-IAMPP. Programa de Investigación Biomédica (PROINBIO)
  • Gloria Rieppi Universidad de la República, Facultad de Medicina, Cátedra de Medicina Intensiva. Prof. Agregada
  • Milka Bengochea Universidad de la República, Facultad de Medicina, Instituto de Donación y Trasplante de Células, Tejidos y Órganos. Prof. Agregada
Palabras clave: NEUMONÍA, INFECCIONES COMUNITARIAS ADQUIRIDAS, GENOMICA

Resumen

Las infecciones del tracto respiratorio inferior constituyen un enorme flagelo para la humanidad. La neumonía aguda comunitaria es la principal enfermedad respiratoria por frecuencia y severidad. A pesar de los avances de la medicina moderna, su morbilidad y mortalidad permanecen prácticamente incambiadas.
La respuesta ante un agravio infeccioso es estrictamente individual al estar influida por la estructura genética del huésped.
La medicina genómica procura personalizar y optimizar el diagnóstico, pronóstico y tratamiento mediante el reconocimiento de la influencia que ejercen determinadas variantes genéticas, denominadas polimorfismos, en la susceptibilidad y evolución de las diversas patologías.
Los polimorfismos genéticos son capaces de modificar el riesgo de padecer determinado evento o suceso en una enfermedad específica por lo cual su reconocimiento permite personalizar la interacción entre ambiente y huésped.
En el presente artículo se describen los polimorfismos que están asociados positivamente con la evolución de la neumonía aguda comunitaria y qué aplicaciones clínicas podría tener la medicina genómica.

Citas

(1) Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of Disease Study. Lancet 1997; 349(9061):1269-76.
(2) Isturiz RE, Luna CM, Ramírez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis 2010; 14(10):e852-6.
(3) Uruguay. Ministerio de Salud Pública. Informe de mortalidad por causa y sexo años 2003 a 2008. Montevideo: MSP, 2009. Disponible en: http://www.msp.gub.uy/uc_3791_1.html. Consulta: 6 enero 2011.
(4) Lassera J, Velázquez A, Pedreira W, Bagnulo H. Neumonía aguda comunitaria del adulto: etiología, estado actual de tratamiento y prevención. Rev Méd Urug 1995; 11(1):27-35.
(5) Bagnulo H, Laserra J, Barros A, Goñi M. Neumonías agudas domiciliarias graves: características, etiología, análisis de factores de riesgo y propuestas terapéuticas. Paciente Crit (Uruguay) 1996; 9(1): 18-32.
(6) Soca A, Bazet C, Batisttesa S, Bono C, Elicabe M, Bentancour S. Neumonías comunitarias graves. Paciente Crit (Uruguay) 1999; 12(2-3):96-107.
(7) Correa H. Neumonía comunitaria severa en Medicina Intensiva. Congreso Uruguayo de Medicina Intensiva, 7. Montevideo. Octubre 2001.
(8) Rodríguez A, Mendia A, Sirvent JM, Bercenilla F, de la Torre-Prados MV, Solé-Violán J, et al. CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35(6):1494-8.
(9) Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. National vital statistics reports. Vol. 49. No. 8. Hyattsville, Md: National Center for Health Statistics, 2001.
(10) Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113(3):227-42.
(11) Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA 1995; 274(4):338-45.
(12) Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term health-related quality of life in survivors of sepsis: Short Form-36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000; 28(11):3599-605.
(13) Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90(2):223-9.
(14) Waterer GW, Wunderink RG Genetic susceptibility to pneumonia. Clin Chest Med 2005; 26(1):29-38.
(15) Varmus H. Ten Years on- the human genome and medicine. N Engl J Med 2010; 362(21):2028-9.
(16) Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291(5507):1304-51.
(17) Hong KW, Oh B. Overview of personalized medicine in the disease genomic era. BMB Rep 2010: 43(10):643-8.
(18) International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437(7063):1299-320.
(19) International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449(7164):851-61.
(20) Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, et al. How to use an article about genetic association. A: background Concepts. JAMA 2009; 301(1):74-81.
(21) Turner MW. Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998; 199(2):327-39.
(22) Sastry K, Herman GA, Day L, Deignan E, Bruns G, Morton CC, et al. The human mannose-binding protein gene: exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989; 170(4):1175-89.
(23) Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155(6):3013-20.
(24) Pérez-Castellano M, Peñaranda M, Payeras A, Milà J, Riera M, Vidal J, et al. Mannose-binding lectin does not act as an acute-phase reactant in adults with community-acquired pneumococcal pneumonia. Clin Exp Immunol 2006; 145(2):228-34.
(25) García-Laorden MI, Solé-Violán J, Rodríguez de Castro F, Aspa J, Briones ML, et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol 2008; 122(2):368-74.
(26) Boeken U, Feindt P, Zimmermann N, Kalweit G, Petzold T, Gams E. Increased preoperative C-reactive protein (CRP)-values without signs of an infection and complicated course after cardiopulmonary bypass (CPB)-operations. Eur J Cardiothorac Surg 1998; 13(5):541-5.
(27) Mätzke S, Biancari F, Ihlberg L, Albäck A, Kantonen I, Railo M, et al. Increased preoperative C-reactive protein level as a prognostic factor for postoperative amputation after femoropopliteal bypass surgery for CLI. Ann Chir Gynaecol 2001; 90(1):19-22.
(28) Póvoa P, Almeida E, Moreira P, Fernandes A, Mealha R, Aragão A, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med 1998; 24(10):1052-6.
(29) Mukamal KJ, Pai JK, O'Meara ES, Tracy RP, Psaty BM, Kuller LH, et al. CRP gene variation and risk of community-acquired pneumonia. Respirology 2010; 15(1):160-4.
(30) van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61(3):189-202.
(31) Sanders LA, Feldman RG, Voorhorst-Ogink MM, de Haas M, Rijkers GT, Capel PJ, et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63(1):73-81.
(32) Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, et al. On the interaction of IgG subclasses with the low affinity FcgammaRIIa (CD32) on human monocytes, neutrophils, and platelets: analysis of a functional polymorphism to human IgG2. J Clin Investig 1992; 90(4):1537-46.
(33) Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30(1):25-8.
(34) Endeman H, Cornips MC, Grutters JC, van den Bosch JM, Ruven HJ, van Velzen-Blad H, et al. The Fcgamma receptor IIA-R/R131 genotype is associated with severe sepsis in community-acquired pneumonia. Clin Vaccine Immunol 2009; 16(7):1087-90.
(35) Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163(7):1599-604.
(36) Schaaf B, Rupp J, Muller-Steinhardt M, Kruse J, Boehmke F, Maass M, et al. The interleukin-6 -174 promoter polymorphism is associated with extrapulmonary bacterial dissemination in Streptococcus pneumonia infection. Cytokine 2005; 31(4):324-8.
(37) Solé-Violán J, de Castro F, García-Laorden MI, Blanquer J, Aspa J, Borderías L, et al. Genetic variability in the severity and outcome of community-acquired pneumonia. Respir Med 2010; 104(3):440-7.
(38) Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30(1Suppl):S58-S63.
(39) Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors: a twin study. Genes Immun 2002; 3(7):407-13.
(40) Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349(9046):170-3.
(41) Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003; 58(2):154-6.
(42) Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24(1):1-8.
(43) Galley HF, Lowe PR, Carmichael RL, Webster NR. Genotype and interleukin-10 responses after cardiopulmonary bypass. Br J Anaesth 2003; 91(3): 424-6.
(44) Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3(10):791-800.
(45) Cohen J, Guyatt G, Bernard GR, Calandra T, Cook D, Elbourne D, et al. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001; 29(4):880-6.
(46) Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 2001; 27(8):1412-5.
(47) Bozza FA, Gomes RN, Japiassú AM, Soares M, Castro-Faria-Neto HC, Bozza PT, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22(4):309-13.
(48) Gando S, Nishihira J, Kobayashi S, Morimoto Y, Nanzaki S, Kemmotsu O. Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med 2001; 27(7):1187-93.
(49) Yende S, Angus DC, Kong L, Kellum JA, Weissfeld L, Ferrell R, et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J 2009; 23(8):2403-11.
(50) Christians ES, Yan LJ, Benjamin IJ. Heat shock factor 1 and heat shock proteins: critical partners in protection against acute cell injury. Crit Care Med 2002; 30(1 Suppl):S43-S50.
(51) Waterer GW, ElBahlawan L, Quasney MW, Zhang Q, Kessler LA, Wunderink RG. Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit Care Med 2003; 31(5):1367-72.
(52) Determann RM, Millo JL, Garrard CS, Schultz MJ. Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation. Intensive Care Med 2006; 32(6):946-7.
(53) Günther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161(2 Pt 1):454-62.
(54) Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268(15):10739-4.
(55) Yende S, Angus DC, Ding J, Newman AB, Kellum JA, Li R, et al. 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia. Am J Respir Crit Care Med 2007; 176(11):1129-37.
(56) Sapru A, Hansen H, Ajayi T, Brown R, Garcia O, Zhuo H, et al. 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia. Anesthesiology 2009; 110(5):1086-91.
(57) Madách K, Aladzsity I, Szilágyi A, Fust G, Gál J, Pénzes I, et al. 4G/5G polymorphism of PAI-1gene is associated with multiple organ dysfunction and septic shock in pneumonia induce severe sepsis: prospective, observational, genetic study. Crit Care 2010; 14(2):R79.
(58) van Iwaarden JF, Claassen E, Jeurissen SH, Haagsman HP, Kraal G. Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am J Respir Cell Mol Biol 2001; 24(4):452-8.
(59) Quasney MW, Waterer GW, Dahmer MK, Kron GK, Zhang Q, Kessler LA, et al. Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. Crit Care Med 2004; 32(5):1115-9.
(60) Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37:517-54.
(61) Okinaga S, Takahashi K, Takeda K, Yoshizawa M, Fujita H, Sasaki H, et al. Regulation of human heme oxygenase-1 gene expression under thermal stress. Blood 1996; 87(12):5074-84.
(62) Yasuda H, Okinaga S, Yamaya M, Ohrui T, Higuchi M, Shinkawa M, et al. Association of susceptibility to the development of pneumonia in the older Japanese population with haem oxygenase-1 gene promoter polymorphism. J Med Genet 2006; 43(4):e17.
(63) Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic biomarker information in drug labels approved the United States Food and Drug Administration: Prevalence of related drug use. Pharmacotherapy 2008; 28(8):992-8.
(64) Raggio V, Roche L. Perfil genómico de riesgo en la práctica clínica. Rev Méd Urug 2009; 25(1):45-58.
(65) Guttmacher AE, Porteous ME, McInerney JD. Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007; 8(2): 151-7.
(66) Esperón P, Raggio V, Goyeneche L, Lorenzo M, Taub I, Stoll M. Genotipo de los genes VKORC1y CYP2C9 en la respuesta individual a la warfarina. Rev Méd Urug 2008; 24(4):266-76.
(67) Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270(24):2957-63.
(68) Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13(10):818-29.
(69) Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22(7):707-10.
(70) International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360(8): 753-64.
(71) Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31(4):1250-6.
(72) Vital M, André F, Esperón P. Farmacogenética y reacción adversa a medicamentos: valor predictivo del polimorfismo en el gen de la uridindifosfato glucuronosil transferasa 1A1. Rev Méd Urug 2010; 26(1):32-38.
(73) Danza A, Cristiani F, Giachetto G. Reacciones adversas a los medicamentos en un servicio de medicina interna del Hospital Universitario. Rev Méd Urug 2010; 26(3):138-44.
(74) Pisabarro R. Nutrigenética y nutrigenómica: la revolución sanitaria del nuevo milenio. Implicancias clínicas en síndrome metabólico y diabetes tipo 2. Rev Méd Urug 2006; 22(2):100-7.
Publicado
2011-04-30
Cómo citar
1.
Cardinal P, Rieppi G, Bengochea M. Medicina genómica aplicada a la neumonía aguda comunitaria. Rev. Méd. Urug. [Internet]. 30 de abril de 2011 [citado 9 de abril de 2020];27(1):42-9. Disponible en: http://revista.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/405
Sección
Trabajos de Revisión o Actualización y Puestas al día